Lotus Pharmaceutical Co., Ltd. (1795.TW)
TWD 260.5
(-1.14%)
TWD 260.5
(-1.14%)
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2023 | 3.77 Billion TWD | 13.38% |
| 2022 | 3.32 Billion TWD | 8.34% |
| 2021 | 3.07 Billion TWD | 39.16% |
| 2020 | 2.2 Billion TWD | 66.85% |
| 2019 | 1.32 Billion TWD | 14.02% |
| 2018 | 1.16 Billion TWD | 25.72% |
| 2017 | 923.35 Million TWD | -4.86% |
| 2016 | 970.56 Million TWD | 7.33% |
| 2015 | 904.3 Million TWD | -15.96% |
| 2014 | 1.07 Billion TWD | 499.87% |
| 2013 | 179.38 Million TWD | 64.65% |
| 2012 | 108.94 Million TWD | -0.4% |
| 2011 | 109.39 Million TWD | 50.46% |
| 2010 | 72.7 Million TWD | -16.01% |
| 2009 | 86.56 Million TWD | 0.0% |
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2024 Q2 | 3.81 Billion TWD | 1.55% |
| 2024 Q1 | 3.75 Billion TWD | -0.59% |
| 2023 Q2 | 3.9 Billion TWD | 8.96% |
| 2023 FY | 3.77 Billion TWD | 13.38% |
| 2023 Q1 | 3.58 Billion TWD | 7.68% |
| 2023 Q3 | 3.92 Billion TWD | 0.43% |
| 2023 Q4 | 3.77 Billion TWD | -3.78% |
| 2022 Q4 | 3.32 Billion TWD | 10.41% |
| 2022 Q3 | 3.01 Billion TWD | -3.43% |
| 2022 Q2 | 3.12 Billion TWD | -1.23% |
| 2022 FY | 3.32 Billion TWD | 8.34% |
| 2022 Q1 | 3.16 Billion TWD | 2.88% |
| 2021 Q3 | 2.55 Billion TWD | -6.06% |
| 2021 Q1 | 2.18 Billion TWD | -0.92% |
| 2021 FY | 3.07 Billion TWD | 39.16% |
| 2021 Q2 | 2.72 Billion TWD | 24.35% |
| 2021 Q4 | 3.07 Billion TWD | 20.23% |
| 2020 Q2 | 1.47 Billion TWD | 13.25% |
| 2020 Q1 | 1.3 Billion TWD | -1.58% |
| 2020 FY | 2.2 Billion TWD | 66.85% |
| 2020 Q4 | 2.2 Billion TWD | 29.59% |
| 2020 Q3 | 1.7 Billion TWD | 15.52% |
| 2019 FY | 1.32 Billion TWD | 14.02% |
| 2019 Q4 | 1.32 Billion TWD | -38.63% |
| 2019 Q3 | 2.15 Billion TWD | -9.12% |
| 2019 Q1 | 2.01 Billion TWD | 73.29% |
| 2019 Q2 | 2.37 Billion TWD | 17.98% |
| 2018 Q2 | 855.79 Million TWD | 0.08% |
| 2018 Q3 | 957.91 Million TWD | 11.93% |
| 2018 FY | 1.16 Billion TWD | 25.72% |
| 2018 Q1 | 855.07 Million TWD | -7.4% |
| 2018 Q4 | 1.16 Billion TWD | 21.19% |
| 2017 Q3 | 974.3 Million TWD | -1.04% |
| 2017 Q4 | 923.35 Million TWD | -5.23% |
| 2017 FY | 923.35 Million TWD | -4.86% |
| 2017 Q1 | 1.08 Billion TWD | 11.31% |
| 2017 Q2 | 984.5 Million TWD | -8.87% |
| 2016 Q4 | 970.56 Million TWD | -1.77% |
| 2016 FY | 970.56 Million TWD | 7.33% |
| 2016 Q3 | 988.01 Million TWD | 0.09% |
| 2016 Q2 | 987.08 Million TWD | 8.74% |
| 2016 Q1 | 907.75 Million TWD | 0.38% |
| 2015 Q1 | 998.96 Million TWD | -7.17% |
| 2015 Q2 | 951.37 Million TWD | -4.76% |
| 2015 Q3 | 893.24 Million TWD | -6.11% |
| 2015 Q4 | 904.3 Million TWD | 1.24% |
| 2015 FY | 904.3 Million TWD | -15.96% |
| 2014 Q1 | 192.5 Million TWD | 7.31% |
| 2014 Q3 | 606.41 Million TWD | 220.57% |
| 2014 Q2 | 189.16 Million TWD | -1.73% |
| 2014 FY | 1.07 Billion TWD | 499.87% |
| 2014 Q4 | 1.07 Billion TWD | 77.45% |
| 2013 Q2 | 149.81 Million TWD | 16.98% |
| 2013 Q3 | 184.87 Million TWD | 23.4% |
| 2013 Q4 | 179.38 Million TWD | -2.97% |
| 2013 FY | 179.38 Million TWD | 64.65% |
| 2013 Q1 | 128.06 Million TWD | 17.54% |
| 2012 FY | 108.94 Million TWD | -0.4% |
| 2012 Q1 | 113.77 Million TWD | 4.0% |
| 2012 Q2 | 113.1 Million TWD | -0.59% |
| 2012 Q3 | 112.19 Million TWD | -0.8% |
| 2012 Q4 | 108.94 Million TWD | -2.89% |
| 2011 Q2 | 112.18 Million TWD | 14.98% |
| 2011 Q1 | 97.56 Million TWD | 34.19% |
| 2011 FY | 109.39 Million TWD | 50.46% |
| 2011 Q4 | 109.39 Million TWD | -16.93% |
| 2011 Q3 | 131.69 Million TWD | 17.39% |
| 2010 Q4 | 72.7 Million TWD | 0.0% |
| 2010 FY | 72.7 Million TWD | -16.01% |
| 2009 FY | 86.56 Million TWD | 0.0% |
| Name | Inventory | Inventory Difference |
|---|---|---|
| Grape King Bio Ltd | 737.18 Million TWD | -412.134% |
| Standard Chem & Pharm CO., LTD. | 1.61 Billion TWD | -133.773% |
| Maywufa Company Ltd. | 257.91 Million TWD | -1363.831% |
| ScinoPharm Taiwan, Ltd. | 1.51 Billion TWD | -149.771% |
| LIWANLI Innovation Co., Ltd. | 60.81 Million TWD | -6107.567% |
| YungShin Global Holding Corporation | 2.77 Billion TWD | -36.146% |
| PhytoHealth Corporation | 163.09 Million TWD | -2214.906% |
| SCI Pharmtech, Inc. | 529.53 Million TWD | -612.964% |
| Formosa Laboratories, Inc. | 1.59 Billion TWD | -136.335% |
| PharmaEssentia Corporation | 1.45 Billion TWD | -158.828% |
| Bora Pharmaceuticals Co., LTD. | 2.15 Billion TWD | -75.1% |